MUMBAI, INDIA--(Marketwired - Jan. 13, 2014) - Diagnos Healthcare (India) Pvt. Ltd. ("DIAGNOS India" or "the Corporation"), a subsidiary of DIAGNOS Inc. (TSX VENTURE:ADK) a leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing, announces the signing of a Letter of Intent to conclude a Channel Agreement with Aditya Jyot Eye Hospital, a leading Ophthalmic Research and Treatment Organization in India.
Under the terms of the LOI, DIAGNOS India will provide its CARA screening services to its client initially in Maharashtra followed by national expansion to areas where Aditya Jyot is active. DIAGNOS India plans to deploy and operate both Mobile and Managed screening services on behalf of the client and screen up to 30,000 patients annually. A formal channel partnership is to be concluded within 90 days.
"We are very pleased to have been selected by Aditya Jyot as a service provider for their screening needs. We very much look forward to serving them and their patients and to working alongside their world-renowned retinal surgeons. The current plan calls for the deployment of a co-branded service including vehicles, cameras, and screening personnel equipped with our internationally recognized CARA platform. We are pleased to have Aditya Jyot's interest and support. We look forward to serving a broader Indian population and helping our client achieve greater practice efficiency through our screening service utilizing our telemedicine platform," said Peter Nowacki, Diagnos Vice-President and Director of Diagnos India.
About Aditya Jyot Eye Hospital
Voted by outlookindia.com as the #1 eye care institution in the State of Maharashtra and #5 overall in India, Aditya Jyot Eye Hospital strives to provide world class eye care service under one roof by innovative service through research, patient-focused care with 100% patient satisfaction, zero percent error, patient education, and innovative services. For more information visit www.adityajyoteyehospital.org.
CARA is a tele-ophthalmology platform that integrates with existing ophthalmic imaging equipment (hardware and software) and processes retinal images at the point of care (POC).The system comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.
About DIAGNOS HEALTHCARE (INDIA) PRIVATE LIMITED
DIAGNOS HEALTHCARE (INDIA) PRIVATE LIMITED was incorporated in Mumbai, Maharashtra, India, under the Indian Companies Act to support and coordinate deployment and usage of CARA in India. It is owned 99% by DIAGNOS Inc. Currently it has one office in Mumbai which serves as a coordination centre for Mumbai and New Delhi mobile screening units.
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.
This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.